{
    "pmcid": "9411660",
    "qa_pairs": {
        "How do multivalent nanobody constructs enhance their therapeutic potential against SARS-CoV-2?": [
            "By increasing binding affinity and neutralization potency",
            "By reducing the risk of viral escape due to mutations",
            "By allowing access to hidden epitopes",
            "By extending the half-life of nanobodies"
        ],
        "What is a significant challenge of using nanobodies as therapeutics, and how can it be addressed?": [
            "Short half-life due to low molecular weight; addressed by engineering multivalent constructs or fusing with Fc regions",
            "Limited access to hidden epitopes; addressed by using bispecific constructs",
            "Low binding affinity; addressed by using prokaryotic expression systems",
            "High production cost; addressed by using E. coli expression systems"
        ],
        "What is the potential advantage of using nanobodies for developing broad-spectrum antivirals?": [
            "Their ability to target conserved viral epitopes",
            "Their high stability and solubility",
            "Their ease of expression in prokaryotic systems",
            "Their small size and unique structure"
        ],
        "What structural feature of nanobodies allows them to bind to cryptic epitopes with high affinity?": [
            "CDR3 being notably longer and more variable",
            "Their small size and unique structure",
            "The presence of four framework regions",
            "The single variable heavy chain domain (VHH)"
        ],
        "Which method is commonly used for screening nanobodies to identify high-affinity binders?": [
            "Phage display",
            "Yeast surface display",
            "Ribosome display",
            "Eukaryotic expression systems"
        ]
    }
}